Tamoxifen, 1 BDBM85467
CHEMBL1213783 BDBM50323911 Tamoxifen methyl iodide
CHEMBL1213784 BDBM50323912 Tamoxifen ethyl bromide
Tamoxifen butyl bromide CHEMBL1213786 BDBM50323914
Tamoxifen isopropyl bromide CHEMBL1213785 BDBM50323913
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine Nolvadex US20240217988, Example Tamoxifen cid_2733526 FOSTRIECIN SODIUM Tamoxifen Tamoxifen (8) CHEMBL83 (2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine NCGC00024928 Tamoxifen, 7 med.21724, Compound Tamoxifen BDBM20607
- Shagufta, na; Ahmad, I Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives. Eur J Med Chem 143: 515-531 (2018)
- Ahmed, NS; Elghazawy, NH; ElHady, AK; Engel, M; Hartmann, RW; Abadi, AH Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism. Eur J Med Chem 112: 171-9 (2016)
- Price, S; Bender, SG; Yahn, R; Till, NA; Varady, S; LaLonde, RL Searching for an ideal SERM: Mining tamoxifen structure-activity relationships. Bioorg Med Chem Lett 52: (2021)
- Bekaii-Saab, TS; Perloff, MD; Weemhoff, JL; Greenblatt, DJ; von Moltke, LL Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A. Biopharm Drug Dispos 25: 283-9 (2004)
- Chao, EY; Collins, JL; Gaillard, S; Miller, AB; Wang, L; Orband-Miller, LA; Nolte, RT; McDonnell, DP; Willson, TM; Zuercher, WJ Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma. Bioorg Med Chem Lett 16: 821-4 (2006)
- Hasegawa, M; Yasuda, Y; Tanaka, M; Nakata, K; Umeda, E; Wang, Y; Watanabe, C; Uetake, S; Kunoh, T; Shionyu, M; Sasaki, R; Shiina, I; Mizukami, T A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor. Eur J Med Chem 71: 290-305 (2014)
- Rivera-Guevara, C; Pérez-Alvarez, V; García-Becerra, R; Ordaz-Rosado, D; Morales-Ríos, MS; Hernández-Gallegos, E; Cooney, AJ; Bravo-Gómez, ME; Larrea, F; Camacho, J Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha. Bioorg Med Chem 18: 5593-601 (2010)
- Carpenter, C; Sorenson, RJ; Jin, Y; Klossowski, S; Cierpicki, T; Gnegy, M; Showalter, HD Design and synthesis of triarylacrylonitrile analogues of tamoxifen with improved binding selectivity to protein kinase C. Bioorg Med Chem 24: 5495-5504 (2016)
- Palermo, AF; Diennet, M; El Ezzy, M; Williams, BM; Cotnoir-White, D; Mader, S; Gleason, JL Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm. Bioorg Med Chem 26: 4428-4440 (2018)
- Tsukuda, S; Kusayanagi, T; Umeda, E; Watanabe, C; Tosaki, YT; Kamisuki, S; Takeuchi, T; Takakusagi, Y; Shiina, I; Sugawara, F Ridaifen B, a tamoxifen derivative, directly binds to Grb10 interacting GYF protein 2. Bioorg Med Chem 21: 311-20 (2012)
- Xiong, R; Patel, HK; Gutgesell, LM; Zhao, J; Delgado-Rivera, L; Pham, TN; Zhao, H; Carlson, K; Martin, T; Katzenellenbogen, JA; Moore, TW; Tonetti, DA; Thatcher, GR Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer. J Med Chem 59: 219-37 (2016)
- Shoda, T; Kato, M; Harada, R; Fujisato, T; Okuhira, K; Demizu, Y; Inoue, H; Naito, M; Kurihara, M Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators. Bioorg Med Chem 23: 3091-6 (2015)
- Kahraman, M; Govek, SP; Nagasawa, JY; Lai, A; Bonnefous, C; Douglas, K; Sensintaffar, J; Liu, N; Lee, K; Aparicio, A; Kaufman, J; Qian, J; Shao, G; Prudente, R; Joseph, JD; Darimont, B; Brigham, D; Heyman, R; Rix, PJ; Hager, JH; Smith, ND Maximizing ER-? Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927. ACS Med Chem Lett 10: 50-55 (2019)
- Govek, SP; Bonnefous, C; Julien, JD; Nagasawa, JY; Kahraman, M; Lai, AG; Douglas, KL; Aparicio, AM; Darimont, BD; Grillot, KL; Joseph, JD; Kaufman, JA; Lee, KJ; Lu, N; Moon, MJ; Prudente, RY; Sensintaffar, J; Rix, PJ; Hager, JH; Smith, ND Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft. Bioorg Med Chem Lett 29: 367-372 (2019)
- Nagasawa, J; Govek, S; Kahraman, M; Lai, A; Bonnefous, C; Douglas, K; Sensintaffar, J; Lu, N; Lee, K; Aparicio, A; Kaufman, J; Qian, J; Shao, G; Prudente, R; Joseph, JD; Darimont, B; Brigham, D; Maheu, K; Heyman, R; Rix, PJ; Hager, JH; Smith, ND Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer. J Med Chem 61: 7917-7928 (2018)
- Lai, A; Kahraman, M; Govek, S; Nagasawa, J; Bonnefous, C; Julien, J; Douglas, K; Sensintaffar, J; Lu, N; Lee, KJ; Aparicio, A; Kaufman, J; Qian, J; Shao, G; Prudente, R; Moon, MJ; Joseph, JD; Darimont, B; Brigham, D; Grillot, K; Heyman, R; Rix, PJ; Hager, JH; Smith, ND Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. J Med Chem 58: 4888-904 (2015)
- Kraft, KS; Ruenitz, PC; Bartlett, MG Carboxylic acid analogues of tamoxifen: (Z)-2-[p-(1, 2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine. Estrogen receptor affinity and estrogen antagonist effects in MCF-7 cells. J Med Chem 42: 3126-33 (1999)